drug, cancer, gastroenterology, diarrhea, pediatrics, endocrinology, IVF, endometriosis, R&D, cognitive impairment
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen also has a significant presence in primary care. In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen started its business in China with a representative office in Tianjin in 1992, and established a joint venture, Beaufour-Ipsen (Tianjin) Pharmaceutical Co, Ltd in the Tianjin Huayuan Industry Park in 1997. After two decades of strong growth, China has become the Group’s second largest market.
Ipsen focuses its resources and investments on three targeted specialty care areas: oncology, endocrinology, and neurology. In these areas, Ipsen operates throughout the entire value chain, from research through to marketing. Ipsen’s commitment to oncology is highlighted by its growing portfolio of key therapies that improve the care of patients with prostate cancer, bladder cancer, neuroendocrine tumors, or other niche oncology diseases. Ipsen is also present in primary care in the symptomatic treatment of certain forms of cognitive disorders in the elderly as well as in gastroenterology with Smecta® and other drugs.